Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 and Rituximab in Refractory Primary ITP
NCT07206823Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of romiplostim in primary immune thrombocytopenia (ITP), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Efficacy evaluation and Incidence of severe Adverse Events up to 12 months. Started Sep 2025; status: recruiting.
02
Drugs
romiplostim
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07206823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07206823.